Cynosure Group LLC Lowers Stock Position in Glaukos Co. (NYSE:GKOS)

Cynosure Group LLC reduced its holdings in Glaukos Co. (NYSE:GKOS) by 29.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,010 shares of the medical instruments supplier’s stock after selling 844 shares during the quarter. Cynosure Group LLC’s holdings in Glaukos were worth $301,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Glaukos by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier’s stock valued at $895,887,000 after acquiring an additional 101,838 shares during the period. Wellington Management Group LLP lifted its stake in shares of Glaukos by 294.5% in the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock valued at $284,501,000 after purchasing an additional 1,630,270 shares during the period. State Street Corp boosted its holdings in Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after buying an additional 98,109 shares in the last quarter. Geode Capital Management LLC grew its position in Glaukos by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier’s stock worth $179,555,000 after buying an additional 25,199 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in Glaukos by 1,235.4% in the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier’s stock valued at $122,374,000 after buying an additional 755,035 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Up 3.1 %

Shares of GKOS opened at $100.07 on Thursday. Glaukos Co. has a twelve month low of $89.94 and a twelve month high of $163.71. The firm has a market capitalization of $5.66 billion, a P/E ratio of -34.87 and a beta of 0.99. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock’s fifty day simple moving average is $126.91 and its 200 day simple moving average is $135.14.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, equities research analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current year.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the company’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Truist Financial boosted their price target on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Needham & Company LLC boosted their price target on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a report on Friday, February 21st. UBS Group initiated coverage on shares of Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price target for the company. Wells Fargo & Company upped their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.